Navigation Links
Certain COPD Meds Might Raise Heart Risks, Study Says
Date:5/21/2013

By Alan Mozes
HealthDay Reporter

MONDAY, May 20 (HealthDay News) -- Long-acting inhaled medications used by millions of people with chronic obstructive pulmonary disease (COPD) may raise the risk of cardiovascular complications among older patients, a new large Canadian study reveals.

The finding centers around patients over age 65 who are prescribed long-acting bronchodilators -- either anticholinergics (such as Spiriva) or beta-agonists (such as Serevent). Both medications are commonly used to relieve the shortness of breath that characterizes moderate to severe COPD and to improve lung function.

The team found that compared with patients who do not use either medication, those using either of these bronchodilators face a notably higher risk for experiencing a cardiac event, such as heart attack or heart failure.

"The bad news is that, although everybody's different, there's a chance that by using these long-acting bronchodilators you may have a mild to moderate risk for cardiovascular problems," said study lead author Dr. Andrea Gershon, a scientist and respirologist in the department of medicine at Sunnybrook Health Sciences Center in Toronto. "The good news is that each of the medications we looked at can also help you if you have COPD."

Gershon said she wouldn't recommend a medication if she didn't think that the benefits outweighed the risks. "And I do. But at the same time I feel the choice has to be made on an individual basis," she said. "And there's an obligation to inform our patients that the risk is there, based on the best evidence we have available, which is this study."

The study appears in the May 20 online edition of JAMA Internal Medicine.

More than one-quarter of Americans over the age of 35 have COPD, which is the nation's number one cause of hospitalization due to chronic illness and the third most common cause of death. Emphysema and chronic bronchitis are commonly associated with COPD.

At issue is not the effectiveness of long-acting bronchodilators. Though they do not slow down disease progression, such medications have long been viewed as solid first-line interventions that help improve a patient's overall quality of life. There is no cure for COPD.

Out of concern over drug-related cardiovascular implications, the study team pored through health care database records for more than 191,000 Ontario residents aged 66 and up, all of them COPD patients newly prescribed long-acting bronchodilator medication at some point between 2003 and 2009.

The investigators found that during the study time frame, 28 percent of the patients experienced a cardiovascular "event" that resulted in their being taken to an emergency department and/or being hospitalized.

Both long-acting medications were linked to a higher risk for experiencing events such as a heart attack or heart failure. Neither drug was linked, however, to a boost in the risk for an irregular heart rhythm or stroke. (Use of anticholinergics appeared to offer a measure of protection against ischemic stroke among newly prescribed users, something not found among beta-agonist users.)

In sum, the authors said the findings indicated that all COPD patients using either type of medication need to be closely monitored for signs of related heart trouble.

"The thing is that we tend to treat diseases as if they're each in a silo," said Gershon, "but in reality they all interact with one another. People with COPD have a number of co-morbidities [or co-existing conditions]. And cardiovascular disease is one of the major ones. So questions regarding risk of this kind are very important for this type of patient population."

Dr. Prescott Woodruff, author of an accompanying editorial and a pulmonologist and critical care specialist at University of California, San Francisco Medical Center, suggested that while the fresh findings are "provocative," much of the prior research has indicated the inhalers are safe to use.

"This study suggests that these dilators might have cardiovascular side effects," he acknowledged, "but it doesn't really prove the point. And, meanwhile, there have been some really, really big clinical trials, done under very controlled conditions, which support the safety of these drugs."

It's possible that those studies may have excluded people with heart disease, Woodruff noted. "So perhaps this research is offering a more real-life point of view," he added, but admitted he's skeptical.

Patients should never stop taking a medication without talking to their doctor first, he said. "But it's certainly worth discussing," Woodruff added.

Although the study found an association between the use of long-acting bronchodilators and cardiovascular complications in older patients, it did not prove a cause-and-effect relationship.

More information

For more on COPD, visit the American Thoracic Society.

SOURCES: Andrea Gershon, M.D., M.S., scientist and respirologist, department of medicine, Sunnybrook Health Sciences Center, Toronto, University of Toronto, and Institute for Clinical Evaluative Sciences, Toronto; Prescott G. Woodruff, M.D., M.P.H., pulmonologist and critical care specialist, and vice-chief of research for pulmonary and critical care division, University of California, San Francisco, Medical Center; May 20, 2013, JAMA Internal Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Voices Against Brain Cancer Comments on New Discovery That May Help MDs Diagnose and Treat Certain Pediatric Brain Tumors
2. Certain Steroids May Raise Risk of Dangerous Blood Clots
3. Certain Parents Less Likely to Follow Doctors Advice: Poll
4. Certain Lifestyle Factors Linked to Arthritis in Study Patients
5. Certain bacteria suppress production of toxic shock toxin: Probiotic potential looms
6. With Certain Strokes, Effects Can Persist a Decade Later
7. Video game exercise for an hour a day may enhance certain cognitive skills
8. Certain Men May Face Higher Risk of Brain Injury
9. Certain Diabetes Medications May Lower Heart Failure Risk
10. Certain Sleep Aids May Raise Hip Fracture Risk in Nursing Homes: Study
11. Obesity, physical inactivity linked with risk for certain molecular subtype of colorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain COPD Meds Might Raise Heart Risks, Study Says
(Date:2/12/2016)... ... 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 ... Winston Churchill said, “Those who don’t learn from history are doomed to repeat it.” , ... come knocking this year. But that takes time. , Take a close look at ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
(Date:2/12/2016)... ... , ... Coco Libre, the maker of coconut water beverages with a purpose, ... Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, ... gifting suite, held this year at the W Hollywood Hotel, has become a pre-show ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5-7. The series is a ... create new habits. The workshops cover a broad range of topics, including coaching ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Every winter, ... , This winter the West Penn Burn Center, part of the Allegheny ... #1, to bring you the “Space Heaters Need Space” campaign. , ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  NOIT™ Research LLC, a private, ... of Change" campaign to assist needy families in obtaining ... unit sold between February 10, 2016 and March 31, ... needy family. The NOIT is an auditory stimulus that ... develop language skills. Beth Shier , ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma ... provider of custom manufacturing and development services for ... sterile fill-finish capabilities and capacity in its ... in demand has driven several recent investments. ... it had one filling line with small-scale lyophilization. ...
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... to announce the acquisition of SolutionsRx, a full-service 340B ... hospitals. Along with providing traditional contract pharmacy services, SolutionsRx ... assist clients in navigating the complex 340B regulatory environment. ... Wellpartner. --> James R. Love , CEO ...
Breaking Medicine Technology: